ArticleGut microbes
Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications.
Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Alternative treatment of recurrentFrontiers in microbiology · 2024Pooled it
- Gut virome dysbiosis contributes to premature ovarian insufficiency by modulating gut bacteriome.Gut microbes · 2026Article
- Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome.Gut microbes · 2026Review
- Review
- Immunotherapy restores therapeutic efficacy of fecal microbiome transplants to treatbioRxiv : the preprint server for biology · 2026Article
- Antibiotic-Driven Gut Microbiome Dysbiosis: Resistome Dynamics, Metabolic Disruption, and Paths to Restoration.Antibiotics (Basel, Switzerland) · 2026Review
- Saccharomyces cerevisiae 48338 Suppresses Antibiotic-Induced Clostridioides difficile Infection in a Murine Model.Probiotics and antimicrobial proteins · 2026Article
- Evaluating the analytical performance of direct-to-consumer gut microbiome testing services.Communications biology · 2026Article
- Probiotic-Derived Extracellular Vesicles as Potential Nano-Immunotherapeutic Platforms in IBD: A Clinician's Perspective.International journal of nanomedicine · 2026Review
- From Womb to World: Unravelling the Microbiota's Impact on Health and Disease.International journal of microbiology · 2026Review
- Carbohydrate competition by Enterobacteriaceae enhances colonization resistance to carbapenem-resistant hypervirulent K. pneumoniae.Microbiome · 2025Article
- Klebsiella ARO112 promotes microbiota recovery, pathobiont clearance and prevents inflammation in IBD mice.Nature communications · 2025Article
- Advances in capsule-based fecal microbiota transplantation: clinical applications and innovations.Journal of translational medicine · 2025Review
- Advanced adhesion and targeting strategies to prolong gut residence time and improve eLBP efficacy in colonic diseases.Advanced drug delivery reviews · 2025Review
- The Microbiota-Gut-Brain Axis in Autism: Associations, Causal Inference, and Interventions-A Narrative Review.Pathogens (Basel, Switzerland) · 2025Review
- Innovative engineering approaches to model host-microbiome interactions in vitro.Advanced drug delivery reviews · 2025Review
- Fecal Microbiota Transplantation in Animals: Therapeutics, Conservation, and Farming.Microorganisms · 2025Review
- Experimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family.Nature communications · 2025Article
- Oral delivery of GLP-1 peptide using recombinantMicrobiology spectrum · 2025Article
- Clinician Management Preferences forOpen forum infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as the primary therapy for initial CDI episodes and suggest alternative approaches for recurrent episodes, including fecal microbiota transplantation (FMT). This paper explores the recent approval of Vowst, a novel oral FMT drug, by the United States Food and Drug Administration (FDA) as a prophylactic therapy to prevent recurrent CDIs. Vowst comprises a formulation of live fecal microbiota spores and works by reestablishing the disrupted gut microbiota, limiting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.